| Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Type/Product Area | Terms/Details (Date) |
| FEBRUARY 2009 | |||
| Novelos Therapeutics Inc. (OTC BB:NVLT) | Mundipharma International Corp. Ltd. (UK) | Agreement to market a cancer drug in Europe and Japan | The $95M deal includes $10M up front and involves NOV-002 for cancer; Novelos will retain all rights and responsibilities in the U.S. and the rest of the Americas (2/12) |
| UCB SA (Belgium; BR:UCB) | Shire plc (UK) | Agreement to acquire the worldwide rights to Equasym IR and XL to treat attention deficit hyper-activity disorder | The rights exclude the U.S., Canada and Barbados; Shire will pay $70.6M, plus small milestone payments in 2009 and 2010; about 20 sales and sales management personnel will transfer to Shire (2/20) |
| MARCH 2009 | |||
| Biota Holdings Ltd. (Australia; PK:BTAHY) | Daiichi Sankyo Co. Ltd. (Japan) | Contract to manufacture and market the firms' long-acting neuraminidase inhibitor CS-8958 in Japan | Biota will receive a royalty on sales and a number of fixed sum payments based on sales milestones (3/30) |
| Eurand NV (Italy; EURX) Ingram Ltd. (South Africa) | Nobel Ilac AS (Turkey); Pharma-Swiss SA (Switzerland); and Adcock | Partnerships to commercialize its extended-release formulation of the muscle relaxant cyclobenzaprine | Nobel will market it in Turkey; Pharma-Swiss will market it in Switzerland; and Adcock will market it in South Africa; terms were not disclosed (3/17) |
| Genzyme Corp. (GENZ) | Bayer AG (Germany) | Agreement giving Genzyme rights to the marketed cancer drugs Campath, Fludara and Leukine, as well as control of the Phase III alemtuzumab program in multiple sclerosis | Genzyme will market alemtuzumab and make contingent revenue-based payments to Bayer, which are capped at $1.25B or 10 years; Bayer also will receive an undisclosed amount of sales-based milestone payments beginning in 2021 unless Genzyme exercises a $900M buyout option in 2020; Genzyme will market all three cancer drugs and make contingent revenue-based payments to Bayer, which are capped at $500M or eight years; Bayer also will receive up to $150M in sales-based milestone payments beginning in 2011; Genzyme will buy a Leukine manufacturing facility for $75M to $100M (3/31) |
| Nitec Pharma AG* (Swtizerland) | Mundipharma International Corp. Ltd. (UK) | Exclusive license agreement for the distribution of Lodotra in Europe, excluding Germany and Austria | Nitec's partner, SkyePharma plc, will receive a mid-single digit royalty on net sales and is manufacturing the product at its Lyon, France, plant (3/31) |
| Somaxon Pharmaceuticals Inc. (SOMX) | H. Lundbeck A/S (Denmark) | Agreement for the worldwide rights for nalmefene, excluding Turkey and South Korea | Lundbeck gained North American and Mexican rights through the new agreement; nalmefene is in Phase III for alcohol dependence (3/12) |
| APRIL 2009 | |||
| InSite Vision Inc. (AMEX:ISV) | Nitten Pharmaceutical Co. Ltd. (Japan) | Exclusive international licensing and distribution agreement for AzaSite 1%, its broad-spectrum antibiotic for bacterial eye infections | Nitten is responsible for securing regulatory approval and has exclusive rights to commercialize the product in Japan and Taiwan; Nitten will pay InSite $1M upon the execution of the license deal, followed by milestone payments of $1M upon regulatory submission and $1M upon first regulatory approval; InSite will receive a double-digit royalty on net sales in Japan (4/2) |
| Interleukin Genetics Inc. (AMEX:ILI) | Labec Pharma SL (Spain) | Agreement giving Labec the rights to market and sell throughout Spain and Portugal its Heart Health genetic test for identifying people at an elevated risk for heart attacks | No financial terms were disclosed (4/6) |
| Nuvera Biosciences* | Veridex LLC (unit of Johnson & Johnson) | Licensing agreement to commercialize assays for predicting patient response to tamoxifen therapy and taxane-containing chemo-therapy in breast cancer | The assays were developed by Nuvera and the University of Texas MD Anderson Cancer Center (4/6) |
| Santen Pharmaceutical Co. Ltd. (Japan; FSE:SZD) | Merck & Co. Inc. | Worldwide licensing agreement for tafluprost, a prostaglandin analogue treatment for glaucoma and ocular hypertension | Santen granted Merck exclusive commercial rights to tafluprost in Western Europe, excluding Germany, North America, South America and Africa (4/15) |
| XenoPort Inc. (XNPT) | GlaxoSmithKline plc (UK) | XenoPort exercised its option to co-promote the drug in the U.S. with GSK | GSK agreed to pay $75M up front and up to $565M in milestone payments for worldwide rights to Solzira, excluding certain Asian territories previously licensed to Astellas Pharma Inc.; GSK also gave Xeno-port ex-U.S. royalty rights and the option to either take royalties or co-promote the drug in the U.S. (4/13) |
|
Notes: # The information in the chart does not cover agricultural agreements or those between biotech companies. * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. AMEX = American Stock Exchange; BR = Brussels Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets. | |||
